The ability to program recombinant gene expression in cardiac myocytes in vivo holds promise for the treatment of many inherited and acquired cardiovascular diseases. In this report, we demonstrate that a recombinant P-galactosidase gene under the control of the Rous sarcoma virus promoter can be introduced into and expressed in adult rat cardiac myocytes in vivo by the injection of purified plasmid DNA directly into the left ventricular wall. Cardiac myocytes expressing recombinant /3-galactosidase were detected histochemically in rat hearts for at least 4 weeks after injection of the f3-galactosidase gene. These results demonstrate the potential of this method of somatic gene therapy for the treatment of cardiovascular disease. (Circulation 1990;82:2217-2221 Somatic gene therapy, the expression of recombinant genes in non-germ-line tissues of the adult organism, holds great promise for the treatment of many inherited and acquired human diseases (reviewed in Reference 1). The biological requirements for this type of gene therapy include the ability to introduce recombinant genes efficiently into the appropriate cells and tissues and to program the high-level and, in many cases, stable expression of these recombinant genes in vivo. In addition, it is necessary that the process of gene therapy itself not be harmful to the recipient organism, in particular, that the techniques used to introduce the recombinant genes do not result in persistent infection of the host or in deleterious mutations of the recipient cells. Two general approaches have proven useful in animal models of somatic gene therapy. In 
Somatic gene therapy, the expression of recombinant genes in non-germ-line tissues of the adult organism, holds great promise for the treatment of many inherited and acquired human diseases (reviewed in Reference 1). The biological requirements for this type of gene therapy include the ability to introduce recombinant genes efficiently into the appropriate cells and tissues and to program the high-level and, in many cases, stable expression of these recombinant genes in vivo. In addition, it is necessary that the process of gene therapy itself not be harmful to the recipient organism, in particular, that the techniques used to introduce the recombinant genes do not result in persistent infection of the host or in deleterious mutations of the recipient cells. Two general approaches have proven useful in animal models of somatic gene therapy. In the first, recombinant genes have been introduced into cultured cells in vitro, and cells expressing the recombinant gene product have then been transplanted into the appropriate tissue of a recipient animal.2-4 In the second, recombinant genes have been introduced directly into somatic cells in vivo.5
The ability to program recombinant gene expression in adult myocardium in vivo requires both an expression vector with high-level activity in cardiac myocytes and a method for introducing such a vector into myocardial cells in the adult animal. A previous study demonstrated that murine skeletal myocytes display a rather unique ability to take up and express DNA after direct injection in vivo.6 In the studies described in this report, we show that an expression vector using the Rous sarcoma virus (RSV) long terminal repeat (LTR) programs high-level recombinant gene expression in rat cardiac myocytes in vitro and demonstrate that recombinant genes cloned into this vector can be introduced into and expressed in adult rat cardiac myocytes for at least 4 48 hours after trunsfection were normalized for protein content and assayed for CAT activity as previously described.9 To control for differences in transfection efficiencies, all transfections also contained 5 pg of the pMSVf3gal reference plasmid. Data are shown as CAT activity relative to that produced by the pS VOCA Tplasmid (which produced 1. 7% acetylation) after correction for differences in transfection efficiency. and added to 1.5 ml of Opti-MEM containing 50 ul of lipofectin reagent (BRL, Gaithersburg, Md.). The resulting mixture was added to one 60-mm plate of cardiac myocytes. After 5 hours at 370 C in 5% C02, 3 ml of Medium 199 plus 5% fetal bovine serum (FCS) (GIBCO) was added to the cells, and the mixture was incubated at 37' C for 48 hours. Cell extracts were prepared and normalized for protein content using a commercially available kit (Biorad, Richmond, Calif.). CAT and ,B-galactosidase assays were performed as previously described.9
Plasmids
The promoterless pSVOCAT plasmid1' and the pRSVCAT11 plasmid in which transcription of the bacterial CAT gene is under the control of the RSV promoter have been described previously. The pRSVf3gal plasmid was constructed by cloning the 4.0-kb 3-galactosidase gene from pMSVf3ga1l2 into HindIII/BamHI-digested pRSVCAT (see Figure 1A ).
Injection of Recombinant DNA In Vivo
Six-to 11-week-old 250-g Sprague-Dawley rats were housed and cared for according to Panel B: 18x view of a 3-mm section from a heart 27 days after pRS Vf3gal injection. Panels C and D: 125x and 250x views; respectively, of 4-M sections from a heart 3 days after pRSVI3gal injection. ,B Galactosidase activity (dark-blue staining) is seen only within cardiac myocytes that can be identified by their myofibnrllar architecture.
Results

RSVLTR Promotes High-Level Gene Expression in Rat Neonatal Cardiocytes In Vitro
Although the RSV LTR displays high-level transcriptional promoter activity in a wide variety of immortalized cell types," previous transgenic studies have suggested that this promoter is preferentially active in skeletal and cardiac myocytes in vivo.13 14 To test directly the transcriptional activity of the RSV LTR in rodent cardiac myocytes, the pRSVCAT vector]' in which expression of the bacterial CAT gene is under the control of the RSV LTR was transfected into primary neonatal rat cardiac myocytes using lipofectin. Two days after transfection, the cultures were harvested and assayed for CAT activity as previously described.9 All transfections also contained 5 gg of the pMSVpgal plasmidl2 to correct for differences in transfection efficiencies. As shown in Figure 1 , the RSV LTR was able to increase transcription of the CAT gene 87-fold compared with the promoterless pSVOCAT control plasmid. The pRSVCAT-transfected cardiac myocyte extracts produced 95% acetylation in a standard thin-layer chromatography assay. (Figures 2A and 2B ). This staining, which was focal and patchy, occurred only in a single area of each heart injected with pRSV,Bgal DNA and was not seen in five control hearts injected with PBS/saline alone (data not shown). Failure to observe staining in two of nine of the pRSV,fgal-injected hearts may have been due to the lack of DNA uptake or expression in these hearts or, more likely, to technical difficulties in successfully centering and anchoring the needle in the relatively thin beating left ventricular wall during the injection process.
Because the normal ventricular wall contains both myocytes and fibroblasts and because the injection of DNA might be expected to cause a localized inflammatory response, it was important to determine which cell types were expressing the recombinant 83-galactosidase gene. Histochemical analysis of sections from hearts injected with the pRSV,3gal DNA clearly demonstrated (3-galactosidase activity within cardiac myocytes that were easily identified by their myofibrillar architecture ( Figures 2C and 2D) . Between one and 10 positively staining myocytes were seen per high-power field, and these were often noncontiguous, suggesting that the uptake of DNA and/or its expression is a relatively low-frequency event. Because it was difficult to accurately identify the extent of DNA injection and because the positively staining areas were quite focal and patchy, it was impossible to accurately quantitate either the percentage or the total number of cells expressing recombinant 3-galactosidase activity in a given heart. However, it is clear that only a small fraction of cardiac myocytes expressed the recombinant protein. In addition, it is worth noting that sections from the 3-5-day postinjection hearts often showed evidence of an acute inflammatory response along the track of the needle ( Figure 2C ) and that in several cases fibrosis along the needle track was observed in sections from the 3-4-week postinjection hearts (data not shown).
Discussion
The studies presented have demonstrated that it is possible to program recombinant gene expression in cardiac myocytes after direct injection of DNA into the left ventricular wall. Functional recombinant protein expression in myocytes was demonstrated directly using an enzymatic assay for ,B-galactosidase. Recombinant gene expression was observed in myocytes from seven of nine of the injected hearts at both 3-5 days and 3-4 weeks after injection. Expression was patchy and was observed only in direct contiguity with the site of injection. These findings have several implications regarding both the use of this method for somatic gene therapy in the heart and the biology of recombinant DNA uptake and expression in muscle cells.
A previous study suggested that murine skeletal muscle cells possess a unique ability to take up and express injected recombinant DNA. 6 Our results have extended this observation to cardiac muscle cells in a second rodent species. It has previously been thought that successful DNA transfection and expression may require recipient cell division and, more specifically, breakdown of the recipient cell nuclear membrane to allow DNA entry. Because skeletal myocytes have a limited potential for mitosiS,15 it remained possible that the previously reported successful transfection of skeletal myocytes was dependent on their mitotic potential. In contrast to skeletal myocytes, adult cardiac muscle cells are unable to divide. 16 Thus, our results demonstrate that mitosis is not necessary for successful transfection of cells with DNA. The mechanisms that allow preferential uptake of DNA into cardiac and skeletal myocytes remain unclear. However, our data suggest that they must be dependent on structural or functional properties that are shared by skeletal and cardiac muscle. Current hypotheses include the possibility of specialized muscle cell transport systems or the unique ability to physically disrupt the cell membranes of muscle cells in a reversible fashion during the recombinant DNA injections.
The technique of somatic gene therapy using direct DNA injection into myocardium, as described in this report, has several advantages compared with other previously described methods of gene therapy. First, infectious viral vectors are not required, eliminating the possibility of persistent infection of the host. Second, a previous study6 has suggested that recombinant DNA taken up and expressed in skeletal myocytes persists as an episome and therefore does not have the same potential for host cell mutagenesis as do retroviral vectors that integrate into the host chromosome. Finally, this method does not require the growth of recipient cells in vitro, a requirement that would render transfection of nondividing cardiac myocytes particularly difficult.
Direct injection of recombinant DNA into the myocardium holds promise for the treatment of many acquired and inherited cardiovascular diseases. We are particularly interested in the possibility of stimulating collateral circulation in areas of chronic myocardial ischemia by expressing recombinant angiogenesis factors locally in the ventricular wall. Although the method described in this report is a first step toward such gene therapy approaches, many questions and problems remain to be addressed 
